Aleksander Prejbisz, Piotr Dobrowolski, Gabriel Bozek, Beata Koń, Aneta Machnio, Witold Śmigielski, Filip Urbański, Filip Nowak, Maciej Miłkowski, Roman Topór-Mądry, Jacek Wolf, Krzysztof Narkiewicz, Pankaj Gupta, Michel Burnier
{"title":"波兰抗高血压药物的处方模式:在全国人口队列中开始和持续治疗的一年评估。","authors":"Aleksander Prejbisz, Piotr Dobrowolski, Gabriel Bozek, Beata Koń, Aneta Machnio, Witold Śmigielski, Filip Urbański, Filip Nowak, Maciej Miłkowski, Roman Topór-Mądry, Jacek Wolf, Krzysztof Narkiewicz, Pankaj Gupta, Michel Burnier","doi":"10.1097/HJH.0000000000004111","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study assessed the prescribing patterns and treatment persistence of antihypertensive medications over a 12-month period in a nationwide cohort from Poland.</p><p><strong>Methods: </strong>We examined data on all 141 668 patients in Poland who received their first hypertension prescription in January 2021, sourced from the e-Health Centre database encompassing all filled prescriptions. Treatment persistence over the first 12 months was assessed as a measure of long-term adherence. We assessed the degree of persistence to therapy as the percentage of patients having a supply of the drug for each consecutive month until the end of follow-up.</p><p><strong>Results: </strong>Antihypertensive therapy was started with a monotherapy in 57% of cases; 23% (21% of women and 25% of men; P < 0.001) started with a two-drug antihypertensive combination and 13% (11% of women, 17% of men; P < 0.001) with a single-pill combinations (SPCs). Only 33% of patients (29% of women, 36% of men; P < 0.001) received drug classes combinations endorsed by guidelines. Treatment persistence after 1 year exhibited significant age-related disparities - persisting in 17-53% among younger and middle-aged individuals, and 59-87% among older patients. Initiation with an SPC was associated with higher 1-year persistence. Among patients still on antihypertensive therapy at 12 months, 30% were on monotherapy, 27% on two drugs, and 43% on three or more agents.</p><p><strong>Conclusion: </strong>In Poland, monotherapy is the predominant first line treatment of hypertension. A substantial proportion of younger and middle-aged patients discontinue therapy within the first year. The use of SPCs at initiation is associated with an improved long-term persistence.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":"1823-1831"},"PeriodicalIF":4.1000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Patterns of prescription of antihypertensive medications in Poland: a one-year assessment of initiation and persistence of therapy in a nationwide population cohort.\",\"authors\":\"Aleksander Prejbisz, Piotr Dobrowolski, Gabriel Bozek, Beata Koń, Aneta Machnio, Witold Śmigielski, Filip Urbański, Filip Nowak, Maciej Miłkowski, Roman Topór-Mądry, Jacek Wolf, Krzysztof Narkiewicz, Pankaj Gupta, Michel Burnier\",\"doi\":\"10.1097/HJH.0000000000004111\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This study assessed the prescribing patterns and treatment persistence of antihypertensive medications over a 12-month period in a nationwide cohort from Poland.</p><p><strong>Methods: </strong>We examined data on all 141 668 patients in Poland who received their first hypertension prescription in January 2021, sourced from the e-Health Centre database encompassing all filled prescriptions. Treatment persistence over the first 12 months was assessed as a measure of long-term adherence. We assessed the degree of persistence to therapy as the percentage of patients having a supply of the drug for each consecutive month until the end of follow-up.</p><p><strong>Results: </strong>Antihypertensive therapy was started with a monotherapy in 57% of cases; 23% (21% of women and 25% of men; P < 0.001) started with a two-drug antihypertensive combination and 13% (11% of women, 17% of men; P < 0.001) with a single-pill combinations (SPCs). Only 33% of patients (29% of women, 36% of men; P < 0.001) received drug classes combinations endorsed by guidelines. Treatment persistence after 1 year exhibited significant age-related disparities - persisting in 17-53% among younger and middle-aged individuals, and 59-87% among older patients. Initiation with an SPC was associated with higher 1-year persistence. Among patients still on antihypertensive therapy at 12 months, 30% were on monotherapy, 27% on two drugs, and 43% on three or more agents.</p><p><strong>Conclusion: </strong>In Poland, monotherapy is the predominant first line treatment of hypertension. A substantial proportion of younger and middle-aged patients discontinue therapy within the first year. The use of SPCs at initiation is associated with an improved long-term persistence.</p>\",\"PeriodicalId\":16043,\"journal\":{\"name\":\"Journal of Hypertension\",\"volume\":\" \",\"pages\":\"1823-1831\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2025-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hypertension\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/HJH.0000000000004111\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/HJH.0000000000004111","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/20 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
Patterns of prescription of antihypertensive medications in Poland: a one-year assessment of initiation and persistence of therapy in a nationwide population cohort.
Objective: This study assessed the prescribing patterns and treatment persistence of antihypertensive medications over a 12-month period in a nationwide cohort from Poland.
Methods: We examined data on all 141 668 patients in Poland who received their first hypertension prescription in January 2021, sourced from the e-Health Centre database encompassing all filled prescriptions. Treatment persistence over the first 12 months was assessed as a measure of long-term adherence. We assessed the degree of persistence to therapy as the percentage of patients having a supply of the drug for each consecutive month until the end of follow-up.
Results: Antihypertensive therapy was started with a monotherapy in 57% of cases; 23% (21% of women and 25% of men; P < 0.001) started with a two-drug antihypertensive combination and 13% (11% of women, 17% of men; P < 0.001) with a single-pill combinations (SPCs). Only 33% of patients (29% of women, 36% of men; P < 0.001) received drug classes combinations endorsed by guidelines. Treatment persistence after 1 year exhibited significant age-related disparities - persisting in 17-53% among younger and middle-aged individuals, and 59-87% among older patients. Initiation with an SPC was associated with higher 1-year persistence. Among patients still on antihypertensive therapy at 12 months, 30% were on monotherapy, 27% on two drugs, and 43% on three or more agents.
Conclusion: In Poland, monotherapy is the predominant first line treatment of hypertension. A substantial proportion of younger and middle-aged patients discontinue therapy within the first year. The use of SPCs at initiation is associated with an improved long-term persistence.
期刊介绍:
The Journal of Hypertension publishes papers reporting original clinical and experimental research which are of a high standard and which contribute to the advancement of knowledge in the field of hypertension. The Journal publishes full papers, reviews or editorials (normally by invitation), and correspondence.